Camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Carlo-Stella, C. Ansell, S. Zinzani, P. L. Radford, John A Maddocks, K. Pinto, A. Collins, G. P. Bachanova, V. Bartlett, N. Bence-Bruckler, I.
Carlo-Stella, C.
Ansell, S.
Zinzani, P. L.
Radford, John A
Maddocks, K.
Pinto, A.
Collins, G. P.
Bachanova, V.
Bartlett, N.
Bence-Bruckler, I.
Citations
Altmetric:
Abstract
Authors
Carlo-Stella, C.
Ansell, S.
Zinzani, P. L.
Radford, John A
Maddocks, K.
Pinto, A.
Collins, G. P.
Bachanova, V.
Bartlett, N.
Bence-Bruckler, I.
Hamadani, M.
Kline, J.
Mayer, J.
Savage, K. J.
Advani, R.
Caimi, P.
Casasnovas, R. O.
Feldman, T.
Hess, B.
Bastos-Oreiro, M.
Iyengar, S.
Eisen, S.
Negievich, Y.
Wang, L.
Wuerthner, J.
Herrera, A. F.
Ansell, S.
Zinzani, P. L.
Radford, John A
Maddocks, K.
Pinto, A.
Collins, G. P.
Bachanova, V.
Bartlett, N.
Bence-Bruckler, I.
Hamadani, M.
Kline, J.
Mayer, J.
Savage, K. J.
Advani, R.
Caimi, P.
Casasnovas, R. O.
Feldman, T.
Hess, B.
Bastos-Oreiro, M.
Iyengar, S.
Eisen, S.
Negievich, Y.
Wang, L.
Wuerthner, J.
Herrera, A. F.
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Carlo-Stella C, Ansell S, Zinzani PL, Radford J, Maddocks K, Pinto A, et al. Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL). Clinical Lymphoma Myeloma & Leukemia. 2022 Oct;22:S347-S. PubMed PMID: WOS:000897948100357.